Olmesartan Krka (Olmesartan Medoxomil)

Olmesartan medoxomil, the active ingredient in Olmesartan Krka, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage high blood pressure in adult patients. GNH USA supplies Olmesartan Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olmesartan Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Krka is an angiotensin II receptor blocker that lowers blood pressure by acting on the renin‑angiotensin system.

- Hypertension: helps lower systolic and diastolic blood pressure in adults. - Heart failure: used as part of combination therapy to improve cardiac output and reduce fluid retention. - Diabetic nephropathy: slows the progression of kidney damage in patients with type 2 diabetes and hypertension. - Post‑myocardial infarction: assists in long‑term blood‑pressure control after a heart attack.

Olmesartan Krka may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness : light‑t    - Headache : oc   - Fatigue : - Upper   -   - 

Serious or Rare Side Effects: -   t . - . - . - . - . - . - . - . - . - . - . - . - . - . - . - . - .

Olmeset  

   t  t.

   .